Lukasiewicz, E <br/><br/>
Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.  [electronic resource] 

 -  Journal of viral hepatitis  May 2010 
 - 345-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2893.2009.01183.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Antiviral Agents--therapeutic use<br/>Body Mass Index<br/>Female<br/>Genotype<br/>Hepacivirus--classification<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Male<br/>Middle Aged<br/>Models, Statistical<br/>Polyethylene Glycols--therapeutic use<br/>Prognosis<br/>RNA, Viral--blood<br/>Recombinant Proteins<br/>Ribavirin--therapeutic use<br/>Sex Factors<br/>Time Factors<br/>Treatment Failure<br/>Viral Load